Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
AXS-12 statistically significantly reduced cataplexy attacks compared to placebo AXS-12 achieved statistically significant remission of cataplexy compared to placebo AXS-12 statistically...
Source: marketscreener.com